In a randomized trial of 46 infrequent cannabis users, adding CBD at ratios up to 3:1 did not reduce THC-induced memory impairment, psychotic symptoms, or other adverse effects.
Read this if you choose cannabis products based on CBD:THC ratios expecting CBD to reduce THC's negative effects.
No protectionCBD at ratios up to 3:1 did not reduce THC-induced memory impairment or psychotic symptoms
What the researchers found
Participants inhaled vaporized cannabis containing 10mg THC with 0, 10, 20, or 30mg CBD. THC alone impaired delayed verbal recall (d=0.50) and induced positive psychotic symptoms on the PANSS (d=0.69). Adding CBD at any dose did not significantly reduce these effects. CBD also failed to modulate THC's impact on other cognitive, subjective, pleasurable, or physiological measures. Plasma CBD levels showed a clear dose-response, confirming participants were absorbing the CBD — it simply didn't counteract THC.
Why it matters
The widespread belief that CBD can "balance out" THC's harmful effects drives both product marketing and policy decisions. This rigorous trial challenges that assumption for the CBD:THC ratios most common in commercial products.
The numbers in context
- 46 healthy infrequent cannabis users
- THC dose: 10mg across all conditions
- CBD doses: 0, 10, 20, or 30mg (ratios 0:1, 1:1, 2:1, 3:1)
- Memory impairment from THC: d=0.50, p=0.001
- Psychotic symptoms from THC: d=0.69, p=2.41×10⁻⁵
- No significant CBD modulation at any dose
- Dose-response confirmed for plasma CBD levels
How the study worked
Double-blind, within-subject, randomized trial with four drug conditions in counterbalanced order. Inhaled vaporized cannabis. Assessed verbal recall (Hopkins Verbal Learning Task), psychotic symptoms (PANSS), cognition, subjective effects, and serial plasma cannabinoid levels.
Who was studied
46 healthy, infrequent cannabis users
What this study cannot tell us
Tested only acute effects in infrequent users; chronic users may respond differently. Maximum CBD:THC ratio was 3:1; higher ratios were not tested. Single session with vaporized cannabis; other formulations and routes may differ. The 10mg THC dose is moderate.
How to read the evidence
Randomized, double-blind, within-subject crossover trial with objective measures and plasma verification. High-quality evidence for this specific question.
When this study was published
Published in 2023. Directly challenges prevailing assumptions about CBD-THC interactions.
The bigger picture
The "CBD protects against THC" narrative has influenced cannabis product design, regulation, and consumer behavior. This null finding suggests the narrative may be unfounded at commercially relevant ratios, and has direct implications for health policy.
Questions still open
- Would much higher CBD:THC ratios (10:1 or 20:1) show protective effects?
- Does chronic CBD exposure build up a protective effect that acute dosing misses?
- Should product labeling and marketing claims about CBD balancing THC be restricted?
Read the original research
Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 48(6), 869-876
Citation
Englund, Amir; Oliver, Dominic; Chesney, Edward; Chester, Lucy; Wilson, Jack; Sovi, Simina; De Micheli, Andrea; Hodsoll, John; Fusar-Poli, Paolo; Strang, John; Murray, Robin M; Freeman, Tom P; McGuire, Philip. (2023). Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 48(6), 869-876. https://doi.org/10.1038/s41386-022-01478-z